I

Immunovant

143 employees

Immunovant is a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases.

Basic info

Industry

biotechnology research

Sectors

Biotechnology
Autoimmune disease
Pharmaceutical

Date founded

2018

Funding rounds raised

Total raised

$200M

from 5 investors over 5 rounds

I

Immunovant raised $75M on October 4, 2022

Investors: TCG X, Commodore Capital, LP and Logos Global Management, LP

I

Immunovant raised $200M on August 2, 2021

Investors: Roivant Sciences and Frazier Healthcare Partners

FAQ